---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-101073"
form_type: "8-K"
ticker: "CRSP"
cik: "0001674416"
company_name: "CRISPR Therapeutics AG"
filed_at: "2026-03-11T23:59:59+00:00"
generated_at: "2026-05-15T14:51:26.694475+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# CRISPR Therapeutics prices $550M convertible notes due 2031 at 1.125% coupon

## Summary
- Aggregate principal amount upsized from $350M to $550M; net proceeds estimated at ~$536.3M.
- Notes mature March 1, 2031; effective coupon 1.125% (1.7308% after Swiss withholding adjustment).
- Initial conversion price ~$76.56 per share, a 45% premium over $52.80 closing price on March 10, 2026.
- Holders may convert at any time prior to maturity; company may redeem after March 6, 2029 under certain conditions.
- Proceeds for general corporate purposes; closing expected March 16, 2026.

## SEC filing metadata
- accession: 0001193125-26-101073
- form_type: 8-K
- ticker: CRSP
- cik: 0001674416
- company_name: CRISPR Therapeutics AG
- filed_at: 2026-03-11T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1674416/000119312526101073/0001193125-26-101073-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1674416/000119312526101073/crsp-20260310.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-101073
- JSON: https://secwatch.observer/filing/0001193125-26-101073.json
- Plain text: https://secwatch.observer/filing/0001193125-26-101073.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.